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Abbreviation and definition: 
Anonymization: “The process of rendering data into a form which does not identify 
individuals and where identification is not likely to take place” (1) 
Clinical data: “Clinical data can be referred as clinical reports and individual personal 
information collectively”(2) 
Clinical report: “A complete document of clinical overviews, clinical summaries and clinical 
study reports together with the following appendices to the clinical study report” (2) 
Clinical Study Report (CSR): “A detailed document about the methods and results of a 
clinical trial. It is a scientific document addressing safety and efficacy and its content is 
similar to an academic paper” (3) 
Confidence Interval: Cl, “A confidence interval is a range of values calculated by statistical 
methods which includes the desired true parameter. The confidence level of 95% is usually 
selected. This means that the confidence interval covers the true value in 95 of 100 studies 
performed” (4) 
Direct identifier: “Direct identifiers are elements that permit direct recognition or 
communication with the corresponding individuals, e.g. personal names, email addresses, 
telephone numbers, and national insurance numbers” (2, 5) 
European Medicine Agency (EMA): “An European agency that is responsible for scientific 
evaluation, supervision and safety monitoring of medicines in the EU” (6)  
Individual Patient Data (IPD): “The individual data separately recorded for each participant 
in a clinical study” (2) 
Quasi identifier: “Quasi identifiers are variables representing an individual’s background 
information that can indirectly identify individuals, example: sex, age, race, ethnicity, height 





Background: The pressure to share more data and being more transparency of clinical study 
reports has grown and becomes an important topic in recent years. Before clinical data and 
clinical results can be shared they must undergo anonymization. How anonymization of 
clinical data affects the utility is poorly-studied, especially in pharmacoepidemiology.  
Objective: The aim of the study is to describe and evaluate how anonymization of simulated 
clinical data will affect the data utility of pharmacoepidemiological analyses of these data.  
Method: We have simulated five clinical datasets with different characteristics, associations, 
types of outcome and study populations. Suppression, generalization, randomization and k-
anonymity were used as our anonymization approaches. These methods will be evaluated by 
the change in the data and statistical results before and after anonymization. 
Result: K-anonymity and suppression were the methods that affected the simulated clinical 
data the most, while generalization and randomization affected the data least. With k-
anonymity and suppression there is a risk to overestimating the clinical results due to the 
elimination of unique records. On the other hand, generalization and randomization preserved 
the most data utility but they were less effective in anonymizing the data.  
Conclusion: Our study revealed that different anonymization approaches can affect the 
clinical results differently. The more we anonymize a record or attribute, the less utility is 
provided. It is therefore important to construct a balance of data utility and effectiveness of 
anonymization before the clinical data are published. More investigations about how 
anonymization of clinical data affects data utility are needed in order to maximize the benefit 







The pressure to share more data and being more transparency of clinical study reports has 
grown and becomes an important topic for pharmaceutical industry, academic research and 
public health (7). Greater transparency, especially sharing of clinical study has been therefore 
taken into account due to the EU health regulation system development and the 
implementation of new policies. According to European Medicine Agency (EMA)’s annual 
report of 2017, the number of requests for access to documents has increased significantly in 
recent years from 416 requests in 2014 to 865 requests in 2017, and the number of requests of 
pages released following access to document also has increased dramatically from 167 309 
pages in 2014 to 487 092 pages in 2017 (8). Additionally, the usage of clinical data on EMA’s 
website has also increased, and it is more than 4 times more usage of clinical data in 2017 
(with 126 300 views and downloads) compares to 2016 (with 28 079 views and downloads) 
(8). 
Sharing clinical data is thereby an important element for pharmaceutical industry, academic 
research and public health. Shared clinical data can be reused to perform other purposes such 
as meta-analyses, individual patient data meta-analyses, academic researches, 
pharmacoepidemiological researches, systematic reviews and reanalysis to enhance public 
health care (9, 10). Furthermore, sharing clinical data can benefit transparency, reliability of 
data extraction and reuse for new purposes in order to save time and money (11).  While, 
having more data transparency can provide a better understanding in clinical data that can 
enhance innovation and scientific inquiry related to new drugs, developing a more robust 
regulatory system and allowing other medicine developers to learn from past successes and 
failures which can benefit the public health (12-14). The problem with having more 
transparency and sharing clinical data is clinical study reports (CSR), which contain 
individual patient data (IPD) that need to be protected before they publish (1). 
According to policy 0070 which was established in 2014, all studies from the pharmaceutical 
industry in Europa including Norwegian companies due to European Economic Area (EEA) 
Agreement, has to be publicly available and open for everyone right after the publications of 
clinical reports are submitted to EMA (1). Consequently, the clinical data that are generated 
during a clinical study will be shared and is open for everyone to reuse for other purposes and 
analyses. Clinical study reports that are generated during a clinical study will be published, 
while individual patient data will be removed. Since we know that clinical reports and clinical 
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study reports contain personal information which are shared can be at risk to be re-identified 
by a third party, the policy 0070 has particularly emphasized that the protection of personal 
data and commercially confidential information are important (1). Additionally, protecting 
personal data is needed and fundamental because it is enshrined in general data protection 
regulation (GDPR) (15). 
The situation today is the policy 0070 is consisted of two phases (2). The first phase is about 
publishing of clinical reports which has started since 1st Jan 2015. This means all clinical 
study reports, clinical overviews and clinical summaries will be published on EMA’s website 
and are available to access by anyone. Anyone who creates an account on the website will be 
able to access all the clinical study reports and information. While the second phase is 
pertained to publishing of individual patient data which will be implemented in a unknown 
later stage (2). This means everyone in the future can access the clinical reports and IPD as 
long as one creates an account on the website. According to this action, the probability for 
attempting a re-identification will be high since everyone can access these data.  
Therefore, the policy aims to ensure that the data is adequately protected and minimizes the 
potential for unlawful retroactive patient identification that can be conducted by a third party 
(1). Besides, it is also important to emphasize the objectives of this policy. The policy also 
aims to “benefit public health, promote better informed use of medicines, develop new 
knowledge in the interest of public health, secondary data analysis e.g. serious side effect and 





Another thing that must be taken into consideration is how a third party discloses a dataset or 
data. A disclosure from a third party or an adversary will occur normally in three different 
forms: Identity disclosure, membership disclosure and attribute disclosure (16, 17). 
Identity disclosure is a type of disclosures that occurs when an attacker can connect a 
participant’s record in a published dataset. For example, if an attacker knows an individual’s 
name, zip code and gender in a data (table 1). There is a high probability that the individual 
can be singled out of the dataset. Two tables with dataset are presented below to describe 
some examples for identity- and attribute disclosure. Table 1 contains a dataset with four 
patients with their name, zip code, sex, age and their disease condition. Table 2 is an 
anonymized/redacted version of table 1. 
Suppose an attacker knows Bob’s zip code and his disease condition from table 1. It is likely 
that the attacker can re-identify Bob in table 2 which is a partially anonymized/redacted 
version of table 1, even if the name and zip code is redacted. “This is because Bob is the only 
male in the table who lives in zip code 124xx and has diabetes” (16). 
Membership disclosure can occur when an attacker is able to determine an individual’s record 
is whether or not contained in a published dataset (16, 17). Let us assume a dataset that 
contains information on only breast-cancer patients. An attacker can by finding out that a 
patient’s record is contained in the dataset deduce the fact that the patient has breast-cancer. 
This can represent a threat to patient’s privacy (16).   
Attribute or sensitive information disclosure is a threat that occurs when an individual’s 
attribute can be linked with their sensitive information (16, 17). This type of disclosure can 
mostly occur when an individual is already known. For example, assume an attacker knows 
Tine’s age and zip code but not her disease condition from table 1. The attacker can infer or 








Name  Zip code Gender  Age Disease 
Bob green 12455 M 56 Diabetes  
Mark maxi 12655 M 34 Flu 
Tine brown 12344 F 35 Diabetes  
Maria blue 12755 F 61 Asthma 
Table 2: A partially anonymized/redacted version of table 1  
 
Name  Zip code Gender   Age Disease 
- 124xx M >40 Diabetes  
- 126xx M <40 Flu 
- 123xx F <40 Diabetes  




De-identification of the clinical data is therefore necessary, and different approaches are used 
to prevent re-identification, securing the personal privacy and reducing the risk of disclosure 
by a third party or an adversary in order to avoid breaching privacy laws. This de-
identification process called anonymization and was used and recommended by the policy 
0070 (1). 
Anonymization can be simply defined as “a process of masking and de-identifying some 
personal sensitive data or attributes” (5, 9). Moreover, this process must be processed in an 
optimal and convenient way that none of these data can single out an individual or link with 
another identified dataset. “So more precisely, these data shall not belikely reasonably to be 
used by a third party or the controller once the anonymization is applied to the data” (5). 
An identifiable data such as personal data or individual’s attribute is categorized into two 
groups, directly or indirectly -identifiers (5, 9). A direct identifier is defined as patient’s name, 
patient number, patient’s health record, telephone number, etc. such information can ease 
identifying of an individual (9, 18, 19). While, an indirect identifier also termed “quasi-
identifier” can be zip code, age, race, sex, background information, date of birth, clinic visit, 
ethnicity, etc. (9, 16, 17, 19, 20). Such information can be linked with other information, and 
results in a high possibility of identifying an individual (1, 2, 5, 9). Disease code, disease, 
diagnose, test result etc. are sensitive attributes or information that are important for an 
analysis and shall whether be removed or redacted (19). 
The benefit of clinical data is to give an opportunity to other researchers to reuse these data 
for other purposes, to test out new analyses and mining new approaches that can provide a 
new perspective to the original data. It is thereby important to anonymize the personal 
information to secure the usage of these data without risk of personal information breach. 
Therefore, All the personal information in a CSR must be anonymized adequately before it is 
published (to reduce the risk of re-identification), and that means all the direct identifier in a 
CSR must be completely deleted before publishing (9, 17).  Therefore, the focus will be to 
anonymize the quasi-identifiers. The problem is that some quasi-identifiers cannot be simply 
removed or redacted, because these can be critical attribute(s) for analysis (19).  
A well-known re-identification experiment was published by A. Narayanan and V. Shmatikov 
(21). They performed research on a Netflix prize dataset where customers rated on a scale 1-5 
on over 18 000 movies by 500 000 subscribers of Netflix (21). More than 100 million ratings 
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were collected, and publicly released after being redacted. The objective in this study was to 
investigate the risk of re-identification for this publicly released dataset. The ratings were 
redacted and anonymized according to internal privacy policy at Netflix, where all customer’s 
personal information was removed except ratings and dates. The researchers revealed that up 
to 99% of records could be uniquely re-identified in the dataset by using 8 movie ratings and 
dates that had a 14-day error. And they could re-identify 68% of records by using 2 ratings 
and dates with a 3-day error (5, 21). The researcher summarized that there is always a chance 
that some individuals can be re-identified from an anonymized dataset, and any re-
identification may cause a potentially harm for study participants because it can disclose any 
personal information or disease record to the public.  
Anonymization can be conducted by different methods. However, randomization, suppression 
and generalization are the most commonly used methods (22). A record or an attribute can be 
redacted (removed) if suppression is applied or it can be perturbed by noises if randomization 
is used, or the record can be aggregated if generalization is used (table 3). Different methods 
can also be used together to achieve a better strategy. For example, generalization combined 
with suppression. A dataset’s variables will first be aggregated into a group or generalized 
into a more general one and then unique records that stand alone will be removed.  
Free-text, participant’s narrative and free-text variables in a clinical study report will also be 
anonymized in order to minimize the risk of personal data breach. 
To achieve the minimum risk of re-identification as much as possible, different 
anonymization-technique or a combination of different techniques must be used on clinical 
data. Especially, before the clinical data are published and can be accessed by anyone. 
Therefore, clinical study reports will normally be anonymized with suppression (redaction), 
generalization, randomization or/and a combination of these methods due to this concern (22).  
A published clinical study report must ensure that it is impossible to single out an individual, 
has low possibility to link records relating to an individual and has low possibility to deduce 
an individual. Otherwise an analysis of re-identification risk must be performed to examine 
the dataset is sufficient anonymized or not (5).  
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Table 3: An overview of different anonymization techniques 
Technique/method Variable Result 
Redaction/suppression Age The record(s) will be removed from the dataset or 
replaced as missing value 
Aggregation/generalization Weight The records will be combined to a more general group 
(e.g. 150kg, 176kg ,165kg  →150-180kg) 
Noise adding 
/randomization 
Salary Random noises will be added to an attribute (e.g. 





1.3. Suppression  
Suppression is the easiest and most common anonymization method to protect personal 
information. With suppression information is completely removed from a dataset (23). All the 
direct identifiers and indirect identifiers are removed by using this method (17). An example 
is presented in table 4 where postcode and age are removed as a result of suppression, these 
variables are replaced by missing value or denoted (-) (23). There are two types of 
suppression that can be used, the first is vertical suppression such as cell suppression where 
an attribute or a variable is suppressed, and the second is horizontal suppression where a 
participant/patient is totally removed from the dataset. 
The advantage of this technique is to reduce the probability to single out a unique individual 
or a unique record in a dataset, and to mask important information (5, 24). The problem with 
suppression is that some interesting findings in an analysis may be completely removed or 
masked. 
When some indirect identifiers are removed, the study population is also reduced which leads 
to the power of the study may also be reduced. Furthermore, it can induce bias into the dataset 




Variable  Value Suppression 
Postcode 9018 - 
Age 59 - 




Randomization is another of the methods to anonymize data (5). Two techniques are 
commonly used in randomization: noise adding and permutation. Noise adding is a simple 
technique where a value of an attribute is modified or adjusted. It leads to a reduction in re-
identification’s accuracy and the link between data and an individual. A good example (table 
5) is weight and age, for the anonymized dataset an individual’s weight may be adjusted +/- 3 
kilos and the age may be adjusted +/-2, whilst the original dataset is measured the true kilos 
and age. So, the overall distribution is retained but less accurate. 
Another randomization technique is permutation where the values of an attribute are changed 
or relocated with other values in a table. By re-locating the record, the logical relationship or 
statistical correlation of two or more attributes is destroyed. Consequently, “the range and the 
distribution of values is remained the same but the correlations between values and 
individuals are not” (5).  
Table 5: An example of how noise addition work on variables (age and weight) 
Variable Value Randomization 
Age  8,55,35,67 10,53,33,69 (+/-2) 
Weight  58,60,78,90 61,57,81,87 (+/-3kg) 
 
Randomization is a good anonymization method that can mask a record from the original one 
if an attacker doesn’t know the pre-randomized distribution. When noise is added into the 
dataset, it can form an uncertainty for an attacker.   
But the disadvantage is when an attacker knows or finds out the distribution or the 





Generalization is an anonymization method that allows some quasi-identifiers to be 
transformed into a more generalized one. Age can be transformed into age group, date of birth 
can be transformed into a range of dates (months or years) and five character zip code can be 
transformed into three or less character zip code, a city can be transformed into a country or 
continent (9). Figure 1 is an example of generalization with age, zip code and disease 
condition. A data’s precision is reduced by using generalization, and it results a lower risk of 
re-identification (9, 24). 
Zip code Age Disease 
12455 56 Hypertension  
12655 34 COPD 
12344 35 Heart failure 
12755 61 Asthma 
 
A generalization hierarchy is normally used to describe what level a quasi-identifier can be 
generalized into. It is important to have a good balance between privacy protection and data 
utility. Therefore, a generalization hierarchy can often show us how far one shall anonymize 
an attribute. Figure 2 shows an example how age is performed in a generalization hierarchy. 
The advantage of generalization is to mask an attribute or a record without removing it. It will 
be less possible for an individual to be singled out or an individual’s record linked with other 
datasets, since generalization will aggerate the record into groups or intervals. But the 
problem with generalization is that these aggregated records can still be inferred and caused 
membership disclosure. How seriously it can harm an individual or a group of individuals will 
depend on what this attribute is. Another problem with generalization is that some attributes 
cannot be generalized e.g. sex and categorical outcome, since some analyses will be 
meaningless if these attributes are generalized. 
Zip code Age Disease 
12301-12500 >40 CVD 
12501-12800 <40 Lung disease 
12301-12500 <40 CVD  
12501-12800 >40 Lung disease 
Figure 1: An example of generalized data of 4 patients. Left: original dataset, Right: generalized 




Figure 2 A generalization hierarchy of age, 1-80 was divided into 4 groups and 
generalized into interval (1-19) (20-39) (40-59) (60-80). (1-19) (20-39) are generalized 
into (<40) and (40-59) (60-80) are generalized into (>40). At last, (<40) (>40) are 












A popular privacy protecting strategy is k-anonymity. K-anonymity is a more advanced 
combination method that transforms an original dataset into a complicated one and creates 
therefore difficulty for an attacker to disclose the dataset (20). An example (figure 3) where k-
value is 4 (k=4) and the identifiable variables are zip code and age. The k-anonymized dataset 
will have at least 4 records for each value combination of zip code and age (20). This means 
any of the observations that has less than 4 observations in a row that doesn’t contain the 
same attributes in the dataset would be suppressed (25). "A k-anonymized data set has the 
property that each record is similar to at least another k-1 other records on the potentially 
identifying variables” (20). This means “each equivalence class contains at least k records” 
(18). 
It is common to anonymize a data with a suitable k-value, too small value of k (ea. like k=2) 
can lower the weight of any individual in a cluster of attributes (5). It also makes the cluster 
too significant and leads to a higher success rate for any inference attacks. Vice versa, the 
higher value of k, the stronger is the privacy secured. An attribute/a record that is anonymized 
under k-anonymity, will therefore have a maximum probability to be re-identified as 1/k (20, 
26). 
The advantage with k-anonymity is that no observations will be singled out, since the 
attribute(s)/record(s) will be anonymized with a k-value between 2 or more. Furthermore, a k-
anonymized dataset provides difficulty for an attacker to link the dataset with other publicly 
available datasets. 
The problem with k-anonymity is that a lot of records can be suppressed. This means the 
records that don’t achieve the certain k-value (like the example we have in figure 3) are 
suppressed. The more records that do not achieve the k-value, the more records will be 
suppressed. This can cause a bias to the result, loss of interesting information and finding and 









Patient Nr. Zip code Gender  Age Disease 
1 482* M 20-40 Diabetes type 2 
3 482* M 20-40 Diabetes type 2 
7 482* M 20-40 Flu 
8 482* F 20-40 Asthma 
2 901* M 41-70 Flu 
4 901* F 41-70 Asthma 
6 901* F 41-70 Diabetes type 2 
11 901* F 41-70 Hypertension 
5 50** F ≥71 Hypertension 
9 50** M ≥71 Diabetes type 2 
10 50** M ≥71 Hypertension 
12 50** F ≥71 Asthma 
13 5015 M 15 Flu 
Patient Nr. Zip code Gender  Age Disease 
1 4827 M 25 Diabetes type 2 
2 9010 M 62 Flu 
3 4820 M 35 Diabetes type 2  
4 9015 F 55 Asthma 
5 5007 F 85 Hypertension 
6 9011 F 52 Diabetes type 2 
7 4825 M 35 Flu 
8 4821 F 28 Asthma 
9 5003 M 75 Diabetes type 2 
10 5034 M 80 Hypertension 
11 9012 F 68 Hypertension 
12 5058 F 77 Asthma 
13 5015 M 15 Flu 
Figure 3 An example of k-anonymity. Left: Original dataset, Right: Anonymized dataset where k=4. 
Gender and disease are not k-anonymized since these are important information 
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1.7. The situation today 
Different pharmaceutical company is using different anonymization method to protect clinical 
data, and the variation of the methods and the techniques can lead to different types of impact 
(27). This can cause loss of usefulness clinical information, and some interesting findings 
might be missed e.g. serious side effects of a drug. 
According to The Organization for Economic Co-operation and Development (OECD), loss 
of data can be considered as loss of data utility since it can cause an adverse effect that affects 
data’s analytical completeness and analytical validity (28). Therefore, policy 0070 has 
highlighted the balance for the protection personal data whilst retaining scientific value of the 
data is important, especially when these data are considered to be reused for other purposes or 
further analyses (1). 
The advantages of anonymization are to preserve strong privacy and prevent for any possible 
attack and re-identification that can cause a personal data breach. But the disadvantages are 
unsatisfactory for hypothesis generation, loss of data utility and sometimes it can be difficult 
to interpret some clinical results (16). 
Several studies have measured and shown how anonymization can lead to information loss or 
loss of data utility. A study (9) where they have examined the probability of re-identification 
by using some simple anonymization methods has found that if the data is greatly 
anonymized, it results in a lot of information loss. However, if a dataset is not adequately 
anonymized, an attacker or a third party can easily disclose the dataset. Therefore, one shall 
always have a good balance between information loss and risk for privacy breach. Another 
study (20) where they have examined how much information loss k-anonymity can cause has 
found out that an over-anonymized dataset which is produced by k-anonymity, can result in 
high information loss and making the data less useful for subsequent analyses. Several studies 
(17, 19, 27, 29, 30)  have used different anonymization method(s) or/and new anonymization 
algorithm(s) to examine data utility and information loss which anonymization has caused in a 
dataset. A study (19) that has proposed new anonymization algorithm has found out their 
anonymization algorithm is better to preserve data utility and provide less information loss 
than the existing method. Another study (17) has suggested that the existing anonymization 
algorithms are not optimal to use for biomedical data or other data with respect to information 
loss and data utility. They have therefore recommended a new anonymization algorithm to 
solve this problem. While several studies (27, 29, 30) have proposed that new anonymization 
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algorithms or new approaches to achieve higher data utility and less information loss. It is 
important to emphasize that none of these studies has examined how anonymization affects 
clinical data or clinical study report. 
So far, there is only one article that pointed out the data utility can be affected if clinical study 
reports are anonymized as the current policy 0070 (31). The article describes that anonymized 
clinical study reports are difficult to use and often require expertise to read, understand and 
process since these documents are often complex and lengthy. The published data are often 
useless to be reused for other purposes like check for publication bias, check for reporting 
bias, systematic reviews or metanalysis, novel analysis like re-analysis with a different 
method or objective to the original analysis or repeat the original analysis. The authors 
emphasize using the anonymized clinical study report is often a time-consuming process and 
can often require the support from a statistician. They also emphasize that a lot of researchers 
need to request the unpublished data from pharmaceutical trials via data sharing platforms to 
access to individual patient data (IPD). By using individual patient data allows researchers to 
perform more complex research questions. 
The anonymized clinical study report often has limited the endpoint in the published data. 
Research like investigation of a drug’s effectiveness is often hard to perform. In such cases, 
using unpublished data (IPD) can be favorable. 
This article has mostly focused on anonymization that is conducted in free-text, participant’s 
narrative and free-text variables, but they also have emphasized that anonymized clinical 
study report can be difficult to use for subgroup analysis like treatment response across 
different subgroup (e.g. different age-group or different type of patients). 
We can’t find any of studies that have given more details for how anonymization affected the 
clinical data, except the last study which has given us a few details. But how the potential 
clinical data has been affected and what consequences it can lead to, for example for 
quantitative results is still a question. Therefore, in this thesis we will investigate how 







The main aim of the thesis is to describe how anonymization of simulated clinical data will 
affect the data utility of pharmacoepidemiological studies by using various methods of 
anonymization. 
More specifically the study will: 
- Find out how anonymization affects different scenarios e.g. different types of 
outcome? Different study populations? Different frequencies of outcome? Different 
strength of associations between treatment and outcomes? 
- Evaluate the utility of the datasets after anonymization 







3.1. Simulation study 
Simulation study is new empirical experiment-study. Simulation study is generating a dataset 
or a study from existing study or patient data that is not real data. This method is used in 
different areas. For example, simulation study can be used to test bias and confounding that 
can result in a real study. More examples about other way to use simulation is listed in the 
table below (table 6). 
Table 6: An overview of other aspects that simulation study can be used (32) 
- To check algebra (and code), or to provide reassurance that no large error has been made, 
where a new statistical method has been derived mathematically 
- To assess the relevance of large-sample theory approximations (e.g. considering the 
sampling distribution of an estimator) in finite samples. 
- For the evaluation of a new or existing statistical method. Often a new method is checked 
using simulation to ensure it works in the scenarios for which it was designed 
- For comparative evaluation of two or more statistical methods 
- For calculation of sample size or power when designing a study under certain assumptions 
 
In this context, we are using the simulation study in a different aspect. We use simulation to 
create five datasets with known distributions and associations between variables as our pre-
anonymized datasets. Then the datasets will be will be anonymized by four different 
anonymization approaches and these distributions and associations will be compared with the 
pre-anonymized datasets. 
3.2. Study population and design 
We simulated our study dataset as a population with female and male adult participants who 
have chronic symptomatic pulmonary arterial hypertension. Our simulated population was 
inspired by a randomized controlled trial (RCT) that was published via EMA (33). Because of 
the published studies have limited information about patient’s characteristic, comorbidity and 
life-style, we had to simulate additional variables not described in the study report to create 
our dataset. 
We think hypothetically the participant in this study will be treated with two different 
treatments a standard treatment and a new treatment. The standard treatment is anticoagulant 
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therapy such as Warfarin, while the new treatment is «Riociguat». Age, hypertension, 
smoking status, heart failure and diabetes are also simulated at the baseline. 
We decided to simulate five different cases (datasets) (table 7). In Case 1 to 4, we used a 
binary variable as our outcome, while in case 5 we chose to test out a continuous outcome. In 
Case 1, 2, 4 and 5 the study population was 10000 persons, whilst in case 3 the study 
population was reduced to 1000 persons. A chosen seed (set to seed= 100 in Stata) was used 
to provide a direct comparison across cases and to make the data reproducible. A seed is “the 
number with which Stata (the statistic program we used) starts its algorithm to generate the 





Table 7: An overview of case 1-5 with seed set to 100 









1 Large effect size and 
frequent outcome 
10000 3578 2582 6,26 
2 Small effect size and 
frequent outcome 
10000 3578 1710 1,12 
3 Small sample size, small 
effect size and moderate 
frequent outcome  
1000 374 143 1,67 
4 Small effect size and rare 
outcome ** 
10000 3578 50 1,17 
5 Moderate effect size and 
frequent, continuous 
outcome *** 
10000 3578 Range: 




*median odds ratio from 1000 datasets, **The outcome is a side-effect of the drug, ***The outcome is a decrease of 




3.3. Simulation as our approach 
All the variables that are simulated in this study are shown in table 8 and 9. The first table 
(table 8) shows the variables that are used in case 1-4, and their classification, value, type and 
how the continuous variables are distributed. 
In case 5 (table 9) most of the variables remained the same, but the outcome was changed to a 
continuous variable. The outcome in this case is a measurement of the changing of 
millimeters of mercury in systolic blood pressure(mmhg) (35). 
We limited the data set to a few simulated covariables and cofounders, since we wanted to 
focus on the anonymization part and the investigation of how anonymization affect these 
variables. To provide direct comparisons across cases, we used the same coding when 
creating identical variables across datasets except outcome. 
The number of each simulated variable can be varied due to different associations were 
simulated. For example, hypertension in case 1 and case 2. The variable was created with 
same coding and same association with outcome, but the outcome was simulated differently. 
Code for hypertension: gen hypertension = round((runiform()*0.7)+(0.09* 
exposure+0.02*outcome)) 
Outcome in case 1: gen outcome = round((runiform()*0.7)+(0.3* exposure)) 
Outcome in case 2: gen outcome = round((runiform()*0.9)+(0.025* exposure)) 
More detailed association and simulation for each case attached in appendix 8.1-8.5.  
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Table 8:  An overview of variables which are used in case 1-4 with their classification, 
value and distribution 
Variable  Classification and value Type (Distribution) 
Age Range: 42-86 years Continuous (Uniform) 
Sex  1= male, 0= female  Essential and binomial   
Weight Range: 36-100kg Continuous (Normal) 
Treatment  1= new, 0= standard Essential and binomial 
Hypertension  1= have, 0= haven’t Binomial 
Smoking status Range: 0-9 cigars  Continuous (Normal) 
Diabetes type 2 1= have, 0= haven’t Binomial 
Heart failure 1= have, 0= haven’t  Binomial 
Outcome 1= treatment goal achieved,  
0= treatment goal not achieved 




Table 9:  An overview of variables which are used in case 5 with their classification, 
value and distribution  
Variable  Classification and value Type (Distribution)  
Age Range: 42-86 years Continuous (Uniform) 
Sex  1= male, 0= female  Essential and binomial 
Weight Range: 36-100 kg Continuous (Normal) 
Treatment  1= new, 0= standard Essential and binomial 
Hypertension  1= have, 0= haven’t Binomial 
Smoking status Range: 0-8 cigars  Continuous (Normal) 
Diabetes type 2 1= have, 0= haven’t Binomial  
Heart failure 1= have, 0= haven’t  Binomial  
Outcome Range: -9 – 2 mmhg Essential* and continuous 




3.4. Anonymization  
Four anonymization methods are used in this context; suppression, randomization, 
generalization and k-anonymity. 
3.4.1. Suppression 
In this context, cell suppression is used to conduct anonymization in case 1-5 (23). Our 
suppression approach will be based on: eliminating the group of participants that does not 
have at least one observation with same attribute, which means these participants that have 
too many unique attributes that diverge from other participants will be suppressed. The 
following participant’s record will be replaced with a missing value (empty cell). However, 
we will not suppress the essential variables since they might be useful for other purposes. 
3.4.2. Generalization 
For case 1-5, the dataset is generalized all the record to a more general one (table 10) (9). So, 
for the sensitive continuous attribute we will alter it to a range or interval. As for age, this 
attribute is aggregated to 5-years interval (0-45, 5-years interval to 80, then 81 and above). 
The same method is used for weight. All the participants are generalized into 5 kg’s interval 
(0-45, 5kgs interval to 80, then 81 and above). 
For smoking status, we categorized it into different status; non-smoker, light smoker, 
moderate smoker and frequent smoker. 1-3 cigars per day as light smoker, 4-6 cigars per day 
as moderate smoker and ≥ 7 cigars per day as frequent smoker. 
For the other binomial attributes like heart failure, diabetes type 2 and hypertension, we will 
generalize them to a more general one which is a variable called comorbidity that stands for 
all the diseases. We generalized all participates who has heart failure, diabetes type 2 and 
hypertension into the variable (comorbidity).  
In case 5, the outcome will also be generalized into different 4 categories with different 




Table 10: An overview of how generalization is used as our method 
Variable  Generalization 
Age  0-45 years, 5-years intervals 
to 80, and 81 years and above 
Weight 0-45kg, 5kg intervals to 80, 
and 81kg and above 
Diabetes, heart failure, hypertension Comorbidities 
Smoking status 0: non-smoker 
1-3: light smoker 
4-6: moderate smoker 
≥ 7: frequent smoker 
Mmhg Group 0: 0 mmhg and above 
(all positive value)  
Group 1: -1 to -3 mmhg 
Group 2: -4 to -6 mmhg 






For randomization, noise addition is used to reduce the precision of the sensitive records (5). 
We adjusted age with +/- 2 years. As for smoking status we will also do the same. We 
adjusted all the original records +/- 2 cigars for the smoking status and recoding all negative 
value to 0. In addition. We adjusted the variable “weight” with +/- 4 kg to participants. So, all 
the record we adjusted is no longer the true record in the dataset. The same methods are used 
for case 1-5. Additionally, in case 5 the outcome will also be adjusted +/- 2 mmhg.  
3.4.4. K-anonymity 
The general k-anonymity method will be used in our thesis, that means the records will first 
be generalized, then the unique records that retained will be suppressed (5). We have selected 
our k value to be 3 to all records. Therefore, any group of participants that didn’t have at least 
3 observations with same attributes in the dataset was suppressed. 
First, we generalized all the records like we did on generalization (table 10). This means for 
case 1-5, we transformed age into age-group, weight into group of weight, smoking status into 
different categories and made a variable (comorbidity) that stands for all the diseases. 
Furthermore, in case 5 the outcome was also generalized exactly same as we did on 
generalization, where the outcome was generalized into 4 different categories with different 
intervals. 
After we have generalized the variables, a new variable was created to define unique records. 
We used the variable to check through all records and suppressed observations that were less 
than 3 in a group. In order to satisfy k-anonymity as much as possible and the essential 




3.5. Statistical analysis 
Data analysis was performed with the statistical software program Stata MP 15 for windows. 
For all cases, 1000 anonymized datasets were created from using a fixed seed from 100 to 
1100. Multiple logistic regression was used to assess associations while adjusting for potential 
confounding factors. After multiple logistic regression, the Odds ratio (OR) was analyzed and 
used for further evaluations. In order to test the association between the continuous outcome 
and the categorical exposure while adjusting for potential, multiple linear regression was 
used. The regression coefficient was analyzed and used for further evaluations.  
Multiple logistic regression was used to measure our outcome in case 1-4 that was adjusted 
for age, sex, smoking status, diabetes type 2, heart failure and hypertension, while multiple 
linear regression was used to measure our outcome in case 5. The median value of the result 
from of the 1000 analyses was calculated and used for further assessments. The unadjusted 
results of 1000 analyses were also calculated. 
For all cases with a chosen seed (set seed=100), the adjusted pre-anonymized results were 
measured (case 1-4 multiple logistic regression and case 5 multiple linear regression) and 
used to compare with the adjusted anonymized results. This procedure was repeated for each 
of the different anonymization methods in order to measure the change from the correct result 
that was further used to evaluate the data utility. The method that we used to measure data 
utility was similar to one of the methods that was described in this guideline (36). 
Multinomial logistic regression was used with nominal categorical dependent variables to 
estimate the association between outcome and exposure, and to adjust for potential 
confounding factors. The regression coefficient was analyzed and used for further evaluations. 
For generalization and k-anonymity in case 5, multinomial logistic regression was used to 
measure the outcome. The group that was most effective was set as the baseline group (group 
3, table 10), and all other groups were compared with group 3. To be able to compare the 
generalized and the k-anonymized results with pre-anonymized result, we had to divide each 
group’s result with the distance between the selected group and the baseline group. The 
generalized and k-anonymized result for group 0 was divided by 9 since the distance between 
group 0 and baseline group was 9. Group 1 was divided by 6, due to the distance between 
them was 6. Group 2 was divided by 3 since the distance between this group and baseline 
group was 3. The confidence interval for generalization and k-anonymity was not measured in 
case 5 since we could not define it after these results were recalculated. 
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We made an interval of the coverage by sorting the odds ratio (case 1-4) or the regression 
coefficient (case 5) of 1000 datasets ascendingly. The interval of coverage was set at 95%. 
The minimum value of the interval was chosen to be 2,5% which was the odds ratio or the 
regression coefficient of dataset 26 and the maximum value of the interval was chosen to be 
97,5% which was the odds ratio or the regression coefficient of dataset 976. In addition, the 
median was chosen to be 50%. 
This interval was made in each case in order to examine how valid each of the anonymization 
methods were across all cases. If a method after conducting anonymization had a result that 
was not included within the interval, the method had a low probability of containing the actual 
association. 
The significance level was set at 5%.  
A Directed Acyclic Graph (DAG) model (figure 4) “provided an entire graphical, and 
mathematical, model that can help us to minimize bias in the analysis” (37). By adjusting for 





Figure 4 A DAG model for independent, covariate and dependent variable, yellow green 
node indicate independent variable which is exposure of interest, blue node indicate 
dependent variable, white nodes indicate measured variables that we need to adjust for 
which are confounders, and red node indicates unmeasured variable. 1 
  
                                                 
1 http://dagitty.net/development/dags.html?id=TLHAF2  
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3.6. Evaluation of the data utility after anonymization and the effectiveness of the 
anonymization 
Finally, we used two different schemes to evaluate the performance of each method (table 11 
and table 12). One for evaluating the effectiveness of the anonymization, while the other one 
was for evaluating the utility of data after anonymization. Different questions were used to 
evaluate these methods.  
For the effectiveness of anonymization (table 11), we first evaluated which method can single 
out an individual’s record. A new variable was made in order to identify single unique 
records. If a record can be single out, we rated the method with a Yes, if no records could be 
singled out, we rated the method with a No. 
At last, we evaluated a record’s linkability and possibility to be deduced by attacker. This was 
done by determining how many attributes of each participant we can identify. If more than 
three attributes of a participant except the essential attributes can be identified after 
anonymization, this method had a high chance to link with another dataset or be deduced by 
an attacker. We rated this method as high chance. If we cannot identify more than three 
attributes of a participant, we rated this method as low chance. 
For the utility of data after anonymization (table 12). We first evaluated whether the 
anonymized datasets can be used to do other pharmacoepidemiological analyses. This was 
done by determining if each dataset can be used for analyses like sub-group analysis, group-
specific analysis or disease-target analyses. If a dataset was able to be used to perform other 
analyses after an anonymization method was conducted, we rated the method with a Yes. If a 
dataset was not able to perform other analyses after an anonymization method was conducted, 
we rated the method with a No. 
Furthermore, we identified any datasets where the result had changed the statistical 
conclusion. This was done by comparing the confidence interval for each anonymized result 
with the pre-anonymized result. If an anonymized result had changed the confidence interval 
from significance to nonsignificant or vice versa, we rated it as Yes, and if an anonymized 
result had not changed the confidence interval (from significance to nonsignificant or vice 
versa), we rated it as No. 
As for information loss, we counted how many records or participants that was eliminated 
during anonymization. Only the number of participants that was used in the statistical 
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analyses was counted. If a method had over 20% of information loss, we rated it as Very 
much. If the method had less than 20% information loss, we rated it as Slightly, and if the 
method did not have any information loss, we rated it as None. 
We also evaluated how valid the result was after anonymization. This was done by measuring 
the differential of odds ratio/regression coefficient between the anonymized result and the 
pre-anonymized result in percentage. If odds ratio/regression coefficient had changed more 
than 5%, we rated it as less valid. If it changed less than 5% but more than 1%, we rated it as 
Moderate. If the result changed less than 1%, we rated it as Very much. 
Table 11 evaluation scheme for the effectiveness of the anonymization  
Effectiveness of anonymization 
1. Can an individual’s record be singled out? Yes/No 
2. Can an individual’s record link with other record or deduce by an attacker?  
High chance /Low chance 
 
Table 12 evaluation scheme for the utility of data after anonymization  
Utility of data after anonymization 
1. Is the data able to perform other analyses like subgroup analysis or other 
pharmacoepidemiological analyses after anonymization? Yes /No 
2. Does the statistical conclusion changed after anonymization? Yes /No 
3. Any loss of information after anonymization? Very much/Slightly/ None 
4. How valid is the result after anonymization?  






Simulated dataset and hypothetical participant were used in this study. Therefore, no real 
patient data or personal preserved data were used. No approval for the information was 








Using 1000 simulations (table 13 and table 14), we found out the odds ratio for case 1 to be 
6,16 which was adjusted for sex, age, weight, hypertension heart failure, smoking status and 
diabetes type, and the unadjusted odds ratio was 6,26. For case 2 where the outcome was low 
associated, the adjusted odds ratio was 1,10 and the unadjusted odds ratio was 1,12. For case 
3 where the sample size is small, the adjusted was 1,65 and the unadjusted odds ratio was 
1,67. For case 4 where the outcome was an infrequent event, the adjusted odds ratio was 1,15 
and the unadjusted odds ratio was 1,17. For case 5 where the outcome is a continuous 
variable, the adjusted regression coefficient was estimated -1,54 and the unadjusted regression 





Table 13 result for the pre-anonymized dataset adjusted for sex, age, weight, 
hypertension, heart failure, smoking status and diabetes type 2 
 Case 1 Case 2 Case 3 Case 4 Case 5 
Median odds ratio 6,16 1,10 1,65 1,15 -1,54 
Standard deviation 0,05 0,04 0,14 0,19 0,02 
95% interval of coverage 5,63- 6,78 1,01- 1,20 1,25-2,16 0,76-1,64  -1,50 –  
(-)1,59 
 
Table 14 unadjusted result for the pre-anonymized dataset  
 Case 1 Case 2 Case 3 Case 4 Case 5 
Median odds ratio  6,26 1,12 1,67 1,17 -1,55 
Standard deviation 0,05 0,04 0,14 0,19 0,03 






4.1. Anonymization  
All the anonymization methods have differently affected the result, and all the results we got 
from multiple logistic regression, multiple linear regression and multinomial logistic 
regression were adjusted for sex, age, weight, hypertension, heart failure, smoking status and 
diabetes type 2.   
4.1.1. Case 1 - large effect size and frequent outcome 
In case 1, the generalization and randomization had the smallest change (table 15). While, 
suppression and k-anonymity changed the result significantly. After generalization was 
conducted the Odds ratio was 6,19 with a change around 0,42%. For randomization the odds 
ratio was 6,16 with a change around -0,01%. K-anonymity and suppression affected the result 
most, with a change around 41,38% for k-anonymity and 336,96% for suppression. The odds 
ratio was 8,72 for k-anonymity and 26,93 for suppression. The confident interval of each 
methods had changed but did not affected the statistical conclusion. 
Table 15 Pre-and anonymized result for case 1  
Case 1 Odds ratio % changed Confidence 
interval  
Pre-anonymized 6,16 - 5,62-6,76 
Generalization 6,19 0,42 5,64-6,78 
Randomization 6,16 -0,01 5,62-6,76 
k-anonymity 8,71 41,38 7,85-9,66 




4.1.2. Case 2 - small effect size and frequent outcome 
In this case, the association between exposure and outcome was lower. After anonymization 
was conducted, the result (table 16) also changed but not as much as case 1. We found out 
generalization and randomization had the same pattern as case 1, where these methods had a 
lower change on the result. The Odds ratio was around 1,09 for generalization and 1,08 for 
randomization. These methods changed the result with 0,23% for generalization and 0,01% 
for randomization. The k-anonymity and suppression didn’t change the result as much as in 
case 1. The odds ratio was 1,10 for k-anonymity and 1,01 for suppression with a change 
around 1,45% for k-anonymity and -6,41% for suppression. We observed that the confident 
interval had changed for k-anonymity (1,01-1,20), and the statistical conclusion had changed 
from nonsignificant to significant. 
Table 16 Pre-and anonymized result for case 2  
Case 2 Odds ratio % changed Confidence 
interval  
Pre-anonymized 1,08 - 0,99-1,18 
Generalization 1,09 0,23 0,99-1,18 
Randomization 1,08 0,01 0,99-1,18 
k-anonymity 1,10 1,45 1,01-1,20 





4.1.3. Case 3 - small sample size, small effect size and moderate frequent outcome 
In case 3 the sample size was reduced to 1000. The odds ratio was 1,43 after generalization 
was conducted and the odds ratio was 1,41 after randomization was used (table 17). In 
addition, generalization and randomization had a slightly change to the result, they changed 
result with 1,67% for generalization and 0,01% for randomization. While, k-anonymity had a 
higher change to the result with 9,39% and the odds ratio was 1,54. Suppression was unable to 
measure due to too many unique records were suppressed. Although the essential variables 
were retained, the logistic regression was unable to use because too many of the adjusted 
variables were suppressed. K-anonymity had also changed the confident interval significantly 
(0,80-2,98), and the statistical conclusion had changed from significant to nonsignificant.   
Table 17 Pre-and anonymized result for case 3 
Case 3 Odds ratio % changed Confidence 
interval  
Pre-anonymized 1,41 - 1,07-1,85 
Generalization 1,43 1,67 1,09-1,88 
Randomization 1,41 0,01 1,07-1,85 
k-anonymity 1,54 9,39 0,80-2,98 




4.1.4. Case 4 - small effect size and rare event 
In case 4, we had an infrequent event as our outcome. We found out that it was very hard to 
optimize the anonymization in this case, since the participant who had infrequent event also 
had a lot of unique record. Consequently, we were not able to use logistic regression after k-
anonymity or suppression was conducted, because many of participant’s records were 
suppressed. Generalization and randomization were the most optimal techniques in this case. 
The odds ratio was 1,29 for generalization and 1,30 for randomization (table 18). We also 
found out these methods had a slightly change on the result with -0,60% for generalization 
and 0,06% for randomization compared to the pre-anonymized dataset.  
Table 18 Pre-and anonymized result for case 4 
Case 4 Odds ratio % changed Confidence 
interval  
Pre-anonymized 1,30 - 0,90-1,89 
Generalization 1,29 -0,60 0,89-1,88 
Randomization 1,30 0,06 0,90-1,89 
k-anonymity - - - 





4.1.5. Case 5 - moderate effect size and frequent, continuous outcome  
We had a continuous outcome in case 5. Since the outcome can be too sensitive we 
anonymized them too, even it can affect the result. In this case, k-anonymity and 
generalization had to use multinomial logistic regression due to nominal outcome. While, 
multiple linear regression was used in randomization and suppression. We found out the 
regression coefficient was -1,55 for randomization and (-)1,61 for suppression (table 19). 
These methods had changed the result with -0,01% for randomization and 3,99% for 
suppression. 
As for generalization and k-anonymity, we found out group 0 had a regression coefficient 
around -2,33 for generalization and -4,17 for k-anonymity. Group 1 had a regression 
coefficient around -0,77 for generalization and -3,56 for k-anonymity. While group 2 had a 
regression coefficient around -0,62 for generalization and -6,02 for k-anonymity. In this case 
k-anonymity had affected the result most with a change around 169,11% for group 0, 
130,18% for group 1 and 288,88% for group 2. Generalization had also changed the result 
significantly but not as much as k-anonymity, it changed the result with 50,54% for group 0, 
(-)50,35% for group 1 and -60,05% for group 2. We can see that k-anonymity and 
generalization were not suitable to use for continuous outcome, even these methods were 





Table 19 Pre-and anonymized result for case 5 
Case 5 Coefficient % changed Confidence interval  
Pre-anonymized -1,55 - -1,50 - (-1,59) 
Generalization     
0 -2,33  50,54 -  
1 -0,77 -50,35  -  
2 -0,62 -60,05 - 
3 Base outcome - - 
Randomization -1,55 -0,01    -1,50 - (-1,59) 
k-anonymity    
0 -4,17 169,11      - 
1 -3,56 130,18 - 
2 -6,02 288,88 - 
3 Base outcome - - 





4.2. The interval of coverage  
For case 1, only generalization and randomization were the methods that were included within 
the interval of coverage, while K-anonymity and suppression deviated from the interval (table 
20). 
For case 2-4, All the methods were included in the interval of coverage, except suppression in 
case 3 and 4 and k-anonymity in case 4.   
For case 5, only randomization was included in the interval, rest of the methods were deviated 
from the interval. Both generalization and k-anonymity could not be defined, since different 
type of analysis was used. 
 
Table 20 The results from case 1-5 and the 95% interval of coverage 
 Case 1 Case 2 Case 3 Case 4 Case 5 
95% interval of coverage 5,63- 6,78 1,01- 1,20 1,25-2,16 0,76-1,64  -1,50 – (-)1,59 
Generalization 6,19* 1,09* 1,43* 1,29* - 
Randomization 6,16* 1,08* 1,41* 1,30* -1,55* 
K-anonymity 8,71 1,10* 1,54* - - 
Suppression 26,93 1,01* - - -1,61 




4.3. Information loss 
As for information loss, only suppression and k-anonymity had information loss across all 
cases (figure 5). In case 1, k-anonymity had a loss around 10,86% and 82,52%for suppression. 
In case 2, k-anonymity had a loss around 10,94% and 84,66% for suppression. In case 3, k-
anonymity and suppression had the highest information loss among all the cases, 66,82% for 
k-anonymity and 98% for suppression. In case 4, k-anonymity and suppression had the least 
information loss among all the cases with 6,24% for k-anonymity and 74,38% for 
suppression. In case 5, k-anonymity had an information loss around 11,94% while 
suppression had an information loss around 88,81%. 
 





4.4. Record identified after anonymization 
Not all the anonymization methods were perfect to anonymize a dataset. Randomization and 
generalization were the only methods that had some records that could be identified after they 
were used (figure 6). In case 1, 5,18% records were identified after generalization and 83,20% 
records were identified after randomization. In case 2, we observed 5,4% records were 
identified after generalization and 85,24% records were identified after randomization.  
In case 3, the dataset only had 1000 records, but we were able to identify 39% records after 
generalization and 97,9% records after randomization. Furthermore, we were able to identify 
3,64% records after generalization and 74,68% records after randomization in case 4.  
In case 5, 6,11% records were identified after generalization was applied and 91,03% records 
were identified after randomization was applied.  
 

































































































































































































4.5. Data utility and Effectiveness of anonymization  
According to the evaluation scheme of data utility, randomization was the method that 
preserved most utility. Generalization was the next method that preserved most utility after 
randomization (table 21). We also found out suppression was the worst method that can be 
used to a dataset since it affected a data very much. All methods behaved similarly in all cases 
for the effectiveness of anonymization, so therefore only one table was made to illustrate the 
effectiveness of each method (table 22). 
K-anonymity was the most effective method to anonymize the data, since this method could 
not single out any records and had low chance to be deduced by an attacker or linked to other 
dataset (table 22). However, this method had low utility compared to generalization and 
randomization (table 21). Generalization, randomization and suppression were the worse 
methods to anonymize a dataset, since these methods could not fulfill the criteria. 
First look at generalization and randomization that performed similarly (table 22). These 
methods had low chance to be deduced by an attacker or linked to other dataset, but they still 
can single out individual records. While suppression was opposite, this method could not 
single out individual records but had high chance to be deduced or linked to another dataset 
by an attacker. It is important to emphasize that records that we were able to single out in 




Table 21 Evaluation for the utility of dataset after anonymization 
 Is the data able to perform 
other analyses like 













How valid is the 
result after 
anonymization? 
Case 1:     
Generalization Yes No None Very much 
Randomization Yes No None Very much 
K-anonymity  Yes No Slightly  Less valid 
Suppression  Yes No  Very much Less valid 
     
Case 2:     
Generalization Yes No None Very much 
Randomization Yes No None Very much 
K-anonymity  Yes Yes Slightly Moderate 
Suppression  Yes No Very much Less valid 
     
Case 3:     
Generalization Yes No None Moderate  
Randomization Yes No None Very much  
K-anonymity  Yes Yes Very much  Less valid 
Suppression  Yes Can’t define Very much Can’t define 
     
Case 4:     
Generalization Yes No None Very much 
Randomization Yes No  None Very much  
K-anonymity  Yes Can’t define Slightly  Can’t define 
Suppression  Yes Can’t define Very much Can’t define 
     
Case 5:     
Generalization Yes Can’t define None Less valid 
Randomization Yes No None Very much 
K-anonymity  Yes Can’t define Slightly  Less valid 




Table 22 Evaluation for the effectiveness of dataset after anonymization: 
 Can an individual’s record be 
singled out? 
Can an individual’s record link with other record or 
deduce by an attacker? 
All cases   
Generalization Yes Low chance 
Randomization Yes Low chance 
K-anonymity  No Low chance 





Our results showed k-anonymity and suppression had the most impact on the result, while 
generalization and randomization had the least impact on the result. In case 1 (large effect size 
and frequent outcome) k-anonymity changed the odds ratio (OR) more than 41%, while 
suppression changed the odds ratio most with 337%. Furthermore, k-anonymity and 
suppression were the only methods that were outside the interval of coverage in case 1 and 
they had an information loss around 11% for k-anonymity and 83% for suppression. The 
result after k-anonymity and suppression was less valid due to the change of the OR. 
Generalization and randomization changed the OR least with less than +/- 1%. 
In case 2 (small effect size and frequent outcome), only suppression had a significant impact 
on the OR with approximately -6% change. Generalization and randomization had the least 
impact on the OR with less than 1% change. K-anonymity had a lower impact on the OR 
compared to suppression with approximately 1% change, but k-anonymity changed the 
confidence interval from nonsignificant conclusion to significant conclusion (from 0,99-1,18 
to 1,01-1,20). Besides, k-anonymity had an information loss around 11%, while suppression 
had an information loss around 85%. The OR after suppression was less valid due to the 
change of the OR, while the OR after k-anonymity was moderate valid. 
In case 3 (small sample size, small effect size and moderate frequent outcome), suppression 
was unable to conduct due to the elimination of the unique records. K-anonymity had the 
most impact on the result with 9% change and a change in the confidence interval from 
significant conclusion to nonsignificant conclusion (from 1,07-1,85 to 0,80-2,98). While 
generalization and randomization had least impact on the result with almost 2% for 
generalization and 0,01% for randomization. K-anonymity also had an information loss 
around 67% and suppression had an information loss around 98%. 
In case 4 (small effect size and rare outcome), k-anonymity and suppression were unable to 
conduct due to the elimination of unique records. while generalization and randomization had 
a small impact on the OR with a change less than +/- 1%. K-anonymity and suppression had 
the least information loss in this case compared to other cases. K-anonymity had an 
information loss around 6% and suppression had an information loss around 74%.  
In case 5 (moderate effect size and frequent, continuous outcome), randomization had the 
least impact on the result with a change around -0,01%. Suppression had a lower impact on 
the result than generalization and k-anonymity with a change around 4%, while generalization 
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and k-anonymity had most impact on the result due to a different analysis method was used. 
For generalization, the result had a change around 50% for group 0, -50% for group 1 and -
60% for group 2. For k-anonymity, the result had a change around 170% for group 0, 130% 
for group 1 and 289% for group 2.  For the information loss, k-anonymity had a loss around 
12%, while suppression had a loss around 89%. The result was less valid after k-anonymity 
and generalization were conducted, while after suppression was conducted the result was 
moderate valid. 
For the effectiveness of anonymization, k-anonymity was the best method to anonymize the 
data, while generalization, randomization and suppression were similarly ineffective to 
anonymize the data. 
First looking at k-anonymity and suppression. These methods had provided less data utility 
due to changes in statistical conclusion, overestimation of result and information loss. This 
concern is most likely due to the elimination of the unique records. For example, k-anonymity 
changed the statistical conclusion in case 2 (small effect size and frequent outcome) from 
nonsignificant to significant conclusion (from 0,99-1,18 to 1,01-1,20), and case 3 (small 
simple size, small effect size and moderate frequent outcome) from significant to 
nonsignificant conclusion (from 1,07-1,85 to 0,80-2,98). The k-anonymity OR changed 
significantly compared to the pre-anonymized OR. For example, in case 1 (large effect size 
and frequent outcome) we can see an overestimation of the result, since the odds ratio 
changed nearly 41% (from OR: 6,16 to 8,71). The overestimation could be a result of 
eliminating cases of non-exposure or eliminating the variables that were combined with non-
exposure in order to achieve k-anonymity. The same pattern of overestimation was observed 
in case 3 with nearly 10% higher than the pre-anonymized OR after k-anonymity was 
achieved. 
A study that examines a new method to preserve the utility better and less information loss in 
2014 (38), has found the similar trend as our result. The study has used k-anonymity (k=100), 
condensation algorithm, two fixed reference points method (TERP) and improved 
microaggregation (as their algorithm) to anonymize the data. They have examined the change 
between the anonymized data and the pre-anonymized data in three statistical analyses (linear 
regression, logistic regression and Cox’s proportional hazards model). These anonymization 
approaches are evaluated by measuring the change in the parameters of these statistical 
analyses (% change of coefficients) before and after anonymization. They have found the 
coefficients in linear regression model, logistic regression model and the exponential values 
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of the coefficients in cox’s proportional hazards model have changed most after k-anonymity 
was used. K-anonymity had highest percentage change of coefficients compared to other 
anonymization approaches, which was similar to our cases where the k-anonymity also had 
high changes. 
The same overestimation problem could be observed in suppression. This method changed the 
result and dataset significantly. The sample size decreased dramatically and caused an 
overestimation like what k-anonymity did in case 1 (large effect size and frequent outcome). 
Suppression changed the OR with approximately 337% (OR from 6,16 to 26,93). Although, 
suppression was a good method to anonymize single unique records, the method was not 
better than generalization and randomization to prevent linkage attack or inference attack (see 
table 22). According to EMA’s clinical data publication report for Oct 2016-Oct 2017(39), 
suppression was the most used method to anonymize data. The problem with suppression is 
variables or/and observations that are eliminated can be essential and critical for the data. In 
other words, eliminating these variables or/and observations can make the data no longer to be 
used for other purposes or/and analyses. Therefore, other methods like randomization and 
generalization or k-anonymity are recommended to use to anonymize data rather than 
suppression (22). 
We have expected k-anonymity and suppression would cause an underestimation due to many 
records were removed, but the result showed these methods had provided overestimation. We 
did not suppress all essential variables in suppression, but still the results were significantly 
affected. All the regression analyses require the completeness of the variables to conduct the 
analysis. Therefore, in suppression the multiple logistic regression analysis and multiple linear 
regression analysis did not include the entire study population. This is because some of 
participant’s variables were suppressed and not included in the analyses. 
A bias might be induced if only the selected records are anonymized and caused an 
overestimation of benefit. As for pharmacoeconomic or health technology assessment, an 
overestimation in a cost-effectiveness analysis can result a better incremental cost-
effectiveness ratio (ICER) for new treatment than the current treatment which leads to higher 
chance for the new treatment to be approved (40). 
A recent simulation study (41) has shown that post-anonymized data or report can lead to 
false conclusions or biases in analyses. This is a study where they have used simulated time to 
event data to examine different methods to improve the accuracy or the validity of the result 
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and reducing the missing time bias that anonymization has created. They have emphasized 
that anonymization has impacted the study results and especially for the time to event data. It 
is therefore important to identify the bias that anonymization can cause and try to adjust them. 
On the other hand, generalization and randomization had the similar performance in 
preserving the utility of clinical data and the effectiveness of anonymization, both had overall 
higher utility than suppression and k-anonymity. We expected these methods would not affect 
the utility very much, but we did not expect that generalization had such a small effect on the 
data, with maximum around 2% changes compared to the pre-anonymized OR across all 
cases. This is because when a variable was generalized in the dataset, only the variable will be 
aggregated, but the overall distribution will be retained. Randomization was expected to have 
a small effect on the data, since all values and distributions were retained, only noise was 
added on the data to reduce the accuracy. 
However, generalization was not good enough to use as a single method to anonymize data, 
since some records were not adequately secured and could be easily singled out an individual 
by an attacker. In our study about 5-7% of unique records were able to be identified after 
generalization was applied. Moreover, when the sample size is lower such as case 3, about 
39% of unique records were able to be identified after generalization was applied. It was 
impossible for generalization to achieve no unique records in our study since not all the 
variables (essential variables) were generalized. 
The same was for randomization too. This method was also not good enough to anonymize 
the record. Records that were transformed by randomization may still have a high risk to be 
re-identified by an attacker, even if an attacker does not know the pre-randomized 
distribution. Assume an attacker knows an individual’s information like age, gender, one of 
the co-morbidities (hypertension, heart failure or diabetes) and outcome. The attacker can use 
the information to predict the rest of data or link them to another dataset to completely 
identify this individual. Therefore, it is not recommended to use randomization as a single 
method to anonymize data. 
Among all cases, case 5 (moderate effect and frequent, continuous outcome) was the only 
scenario where the outcome was also anonymized by different methods. Generalization and k-
anonymity were the methods that had the most impact on the data utility after they were used 
in case 5. The aggregated outcome needed a different type of regression, and therefore 
multinomial logistic regression was used to measure the result. After the analysis was 
62 
 
conducted, the results were not directly comparable with the pre-anonymized coefficient, 
since different type analyses were used. The k-anonymity result and generalization result 
needed to be re-calculated to similar coefficients that were comparable to the pre-anonymized 
coefficient. Due to this problem, k-anonymity and generalization seemed to be the 
inappropriate methods to anonymize continuous data especially continuous outcome. 
For the utility part. The result showed all methods were still able to conduct 
pharmacoepidemiological analyses, but not all the methods were suitable for every 
pharmacoepidemiological analysis. If a result is aggregated, it can be hard to use on a 
subgroup analysis or target specific analysis like examination of the effect in specific age 
group like subgroup analysis for elder participant or subgroup analysis for specific disease 
patient (e.g. cardiovascular disease patient). The problem with aggregated result and 
aggregated data is more apparently in meta-analyses and systematic reviews. To perform a 
meta-analysis or systematic review, all the results and data from the studies that are included 
must be comparable, corresponding or correlated to each other (42). However, using 
aggregated data to conduct these analyses might require highly skilled researcher (31). 
Advantages of using aggregated data are less time consuming and cheap to perform a meta-
analyze compares to use individual patient data (IPD), which are the unpublished data (43). 
Meta-analysis of IPD might be time consuming and expensive, but it allows researchers to 
answer more complex and detailed research questions, additionally to achieve a more valid 
estimation (31). The result in case 5 showed the pre-anonymized outcome provided more 
utility compared to aggregated outcome respectively, to conduct other analysis like meta-
analysis. In addition to this concern, aggregated data and results can be difficult to perform a 
re-analysis of a study to verify the result or the conclusion of the study (31). 
An interval of coverage can indicate which estimate contained the actual result. In our results, 
most of the methods were included in the interval of coverage across the cases, except 
suppression in case 3 and case 4, k-anonymity in case 4 and case 5, and generalization in case 
5. 
The interval of coverage for k-anonymization and generalization in case 5 could not be 
measured, since a different type of regression analysis was used to measure the outcome. But 
for suppression in case 3 and case 4 and k-anonymity in case 4, too many records were 
suppressed and therefore the interval of coverage could not be defined in these methods. 
Across all cases, the validity or accuracy of the anonymized result seemed to be highest or 
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had highest probability to be included within the interval when a dataset had moderate effect 
size, big sample size and frequent outcome to be anonymized without being suppressed. 
In general, most of the utility was preserved when we did not eliminate or suppress any 
records. This might be an important thing to consider when one is considered to use k-
anonymity or suppression to anonymize personal information or important patient record. A 
good example was case 4 where the outcome was an infrequent event, it was impossible to 
conduct any pharmacoepidemiological analysis when most of the participants were 
suppressed. Furthermore, the result could not be measured after suppression or k-anonymity 
were used. 
On the other hand, for the effectiveness of anonymization, k-anonymity was the most optimal 
method to anonymize the data compared to generalization, randomization and suppression. 
Suppression could not avoid high chance of inference attack or link attack since only the 
unique records are suppressed. Assume an attacker has all information to a participant in our 
study, after suppression is applied the attacker still have a 50% chance to identify the 
participant, since two of the participants can have similar information. This is considered to 
have a high probability to successfully re-identify a participant, but if the group of two 
participants that have similar information also be suppressed, the dataset may retain less than 
5-10% study population to use for other purposes or analyses that can consider as low data 
utility. Furthermore, due to the decrease in study population the result might also be less 
reliable and valid. 
Our methodology was based on simple simulation and coding that provided an insight for 
how anonymization of simulated clinical data affects the analysis result and a better 
understanding of anonymization in pharmacoepidemiology. To provide direct comparisons 
across cases, we used the same seed when creating all datasets and same coding when 
creating identical variables across datasets. For the anonymization part, some anonymization 
methods had limitations to anonymize the data and not all anonymization methods were 
suitable for every type of variables. For example, randomization was more suitable to use on 
numeric and continuous variable than categorized variable (44). While, generalization, 
suppression and k-anonymity were suitable for most type of variables. 
Despite, there is always a tradeoff between utility of data and effectiveness of anonymization 
that one needs to consider, no matter how the clinical data will be anonymized. More 
anonymization will preserve less data utility and vice versa. The biggest question due to this 
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concern is what shall pharmaceutical companies do? According to the current situation, 
different pharmaceutical companies have different policies to anonymize the data, and the 
data transparency is therefore very vary (45). A better and global standard for how to 
anonymize clinical data is needed in the future in order to achieve better data utility and more 
transparency. 
An important thing that should be into consideration is open data access. The current problem 
is anyone can access the CSR that are published by EMA. The more people get access, the 
higher is the number to attempt a re-identification. In other words, no matter the available data 
is more or less anonymized, the probability for a third party to perform a re-identification is 
high. Besides, if any pharmaceutical company breaks the general data protection regulation 
(GDPR), they can be fined up to 20 million euros due to the penalty of personal data breach 
(46). A stricter anonymization as the current situation is therefore used to ensure no personal 
data breach, which has also provided low data utility. To achieve better data utility due to this 
problem, a better data access security system must be implemented to regulate the individual 
who accesses these data. This might lead to reduced strictness of anonymization and facilitate 
a better balance between data access and data utility. 
Another important thing to be taken into consideration is publishing of individual patient data 
(IPD) in the future due to phase 2 of policy 0070. IPD might be a better resource to use for 
studying other purposes compares to clinical study report (CSR), since they can provide more 
useful and reliable information. These data might benefit in many aspects. For example, 
pharmacoepidemiological studies like meta-analysis and systematic review since IPD might 
be easier to compare or combine data from different studies. Besides, IPD can provide a better 
understanding and interpretation of a study’s result and conclusion. On the other hand, 
individual patient data are more sensitive than CSR and contain patient’s information and 
important commercially confidential information that can be abused by a third party. Due to 
this problem, pharmaceutical companies might create an anonymization procedure as strict as 
possible in order to protect the personal data, which also can provide low data utility. 
According to the current policy (1), this process is under construction and various aspects 
need to be reviewed and clarified. The policy has stated that their first target is “to undertake 
public consultation with all concerned stakeholders on the various aspects in relation to IPD 
to provide a clarification”(1). What might also need to be clarified is how to share these data. 
A new guideline and policy for how to anonymize these data and who can access these data is 
needed with respect to the patient privacy and commercial confidence. Besides, A new 
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guideline for how to use this type of data is also needed in order to provide a better 
understanding of the disease(s) or/and the treatment(s). 
In addition to data sharing of clinical reports and individual patient data, transparency in 
clinical report and clinical data might also be an important object to taken into account in 
order to benefit public health and pharmaceutical industry. We think a new policy and 
standard that pertain to transparency is also needed in future in order to maximize the utility 
of using clinical data. A better transparency might benefit pharmaceutical industry by making 
the regulatory process clearer and predictable (14). Furthermore, this article (14) has 
emphasized that “transparency might also benefit the public health by allowing medicine 
developers to learn from past successes and failures or enable the wider scientific community 
to make use of detailed clinical data to develop new knowledge. It might also allow other 
researchers to verify original analysis and conclusions, to conduct further analyses, and to 
examine the positions of the regulator and challenge them where appropriate”. 
5.1. The strength and limitation of the study 
The strength of this study was we have created a simulation study which allowed us to know 
the correct result of our analyses and how these gold-standard results change when different 
anonymization techniques are used. The flexibility of simulation study allowed us to examine 
different type of results, adding or changing any variable and its distribution. 
Another strength we had in this study was that by using simulated data, we had no ethical 
challenges in this study. That is because simulated clinical data was used, not real clinical 
data. Otherwise it can be time consuming to get approve for the usage of clinical data and 
solving other ethical problems. Additionally, it was hard to find a good dataset to perform our 
study. 
We have stored the code that we used for the creating the simulated datasets and for the 
anonymization methods that can be re-used or tested for other analyses. This is an advantage 
that allowing other researchers to re-use them for other purposes. Furthermore, our study is 
reliable and transparent since each case can be reproduced. 
As far as we know, there are almost no studies that have examined similar or same objective 
as ours. Thereby, our study is the one of the first studies that investigated how anonymization 
of simulated clinical data affects the analysis and the data utility. Our study can benefit other 
future investigations that examine the data utility after anonymization. 
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There are a few limitations in our study. First at all, only simple anonymization methods were 
used, and no advanced methods like l-diversity and t-closeness were used in this study. The 
reason for why only the simple methods were used is because we want to imitate how clinical 
study report is normally anonymized. Clinical study reports are normally anonymized with 
redaction (suppression), generalization, randomization or/and a combination of these 
methods. 
Secondly, we did not use a real clinical dataset. A real clinical dataset will normally have 
more variables and probably more or less participant than our datasets. In addition, a real 
clinical dataset has often more essential variables that may have vary correlations to each 
other. Therefore, anonymizing these variables might lead to loss of data utility and loss of 
validity. 
Thirdly, we were not able to access all the information from the clinical study report. The 
current clinical study reports have limited useful information to be used for our study (33). 
Therefore, hypothetical and fixed variables and values are created to perform our study which 
can reduce the reliability of the study. 
It is important to emphasize that our evaluations of effectiveness and utility were based on our 
subjective judgement. This can vary from person to person. Since there are no standard 
guidelines to evaluate the effectiveness of anonymization and the data utility, we had to use 
subjective judgement to evaluate the cases. The reliability of the results is therefore reduced. 
More studies in this concern with different evaluations is needed to increase the reliability of 
our results. 
There are a few things we could do differently in this study, for example testing out different 
k-value to see which k preserves most utility. However, we do not assume a higher k will give 
us better utility, and neither could we see a lower k will be more effective to anonymize the 
records. Therefore, A k= 3 is often recommended in studies, but in practice k=5 is often used 
instead (47). However, A k value between 2 and 15 is needed to ensure the data is secured 
(47). A k=5 should be tested to see how much it differ from a k=2. What we could also do 
were instead of using the standard k-anonymity where the record is first generalized and then 
suppressed, we could first add noises to the records then generalize them. This approach may 
have high probability to preserve more utility due to no records will be eliminated. Since the 
records are randomized and generalized the risk of disclosure may also be minimized.  
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Furthermore, we could generalize bigger the intervals or the groups, so more record might be 
included in the interval or group. An advantage with a bigger generalized group is the risk of 
re-identification is reduced since the variable will be less specific (9). But at the same time, 
the utility will also be reduced since the aggregated group or interval is bigger and can be 
more difficult to conduct other pharmacoepidemiological analyses like group specific analysis 
or target specific analysis. 
Besides, we could have some other professionals to test our dataset for linkage attack or 
inference attack to increase the validity or/and reliability for our evaluations. We could give 
10-participant’s information to 10 random persons and let them try to identify those 
participants in the anonymized dataset. Thereafter, we measure and evaluate how many 
participants they could identify to see how effective our anonymization methods were. 
The same thing could be done to examine the re-usability. We could gather 10 random 
persons and let them check the dataset are still usable for other pharmacoepidemiological 
analyses after different anonymization methods are used. We give them the anonymized 
datasets and ask them to perform some specific analyses, then we measure and evaluate how 
many of the analyses they were able to conduct and what kind of analyses they were capable 
to perform. 
Imputation of random value or pre-defined value such as mean or median to replace the 
record we suppressed could be used in this study. Imputing random or pre-defined value may 
retain more utility of the attribute than just suppressing them and leaves the cell empty. The 
most important thing to consider is not imputing all the suppressed record perfectly. Since a 
perfect imputation will just result high chance to recover the pre-suppressed 
value(s)/record(s). A study that examines different strategies to anonymize taxonomic data 
(48) has found that multiple imputation can preserve a high level of data utility and minimize 
the level of disclosure risk. This study has used different anonymization methods like data 
shuffling, microaggregation and multiple imputation to investigate which of them gives most 
utility. 
We could also make a re-identification scale or perform a re-identification analysis to evaluate 
the level of re-identification risk for each variable after anonymization. A study has 
performed an evaluation for the risk of re-identification of patients from hospital prescription 
records (49). The objective of this study was to evaluate the ability to re-identify patients from 
prescription records. They have measured and quantified each anonymized variable with a 
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level of re-identification risk. However, the study has only shown the evaluation of re-
identification risk for generalized or/and suppressed variable. 
Other utility-based measurements could be used in our simulation study. There are a lot of 
approaches for different type of variables that can be used to measure the utility after 
anonymization (36). For example, we could measure the mean or median of each anonymized 
numeric variable and calculate how much they derivate from the pre-anonymized variables. 
Different simulation approaches could also be used in the study like creating more variables 
or covariates, to have bigger sample size, stronger effect size or more frequent outcome. 
5.2. Future investigation 
I would suggest for the future investigation to examine the data utility of using advanced 
anonymization methods like t-closeness and l-diversity or advanced anonymization 
algorithms combining more than one method. It would be interesting to see how much utility 
the advanced methods can preserve and are they still usable for pharmacoepidemiological 
analyses after conducting compare to our finding. Another thing that might be interesting to 
investigate is the utility of real clinical data after anonymization. It can be interesting to 
investigate the differences between real clinical data and our simulated data. 
What might also be interesting to investigate is the data utility of time to event data after 
different anonymization methods were conducted. One can create an immediate outcome like 
immediately treated and a final outcome like death. Then anonymizing these data and 
measuring the utility after anonymization and the effectiveness of anonymization. 
Overall, more investigations about how anonymized clinical data (CSR and IPD) affects data 
utility are needed to maximize the benefit of data sharing and data utility while minimizing 








When we simulated datasets using different anonymization methods they affected the analysis 
results differently. K-anonymity and suppression were the methods that affected the analysis 
results most, while randomization and generalization were the methods that affected the result 
least. There is always a tradeoff between data utility and effectiveness of anonymization. 
Better anonymization will preserve less data utility and reverse.  
For the data utility after anonymization, randomization and generalization were the methods 
that preserved most utility. While for the effectiveness of anonymization, k-anonymization 
was the most effective method to anonymize data.  
Therefore, it is important to construct a good balance before the clinical data are published. 
More investigations about how anonymized clinical data (CSR and IPD) affects data utility 
are needed for conducting other pharmacoepidemiological analyses, and to maximize the 
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8.7. Syntax for anonymization in case 5 


















8.8. Syntax for generating 1000 -datasets and -analyses adjusted for co-variates 
 
